<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357344</url>
  </required_header>
  <id_info>
    <org_study_id>999906173</org_study_id>
    <secondary_id>06-DK-N173</secondary_id>
    <nct_id>NCT00357344</nct_id>
  </id_info>
  <brief_title>Study of Effects From Gastric Bypass Weight Loss on Brain Tissue</brief_title>
  <official_title>Weight Changes and the Brain (Study of the Effects of a Large and Intentional Weight Loss Induced by Roux-en-Y Gastric Bypass on Brain Tissue Composition of Obese Patients Using Magnetic Resonance Imaging and Voxel-Based Morphometry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate how large, intentional weight reduction affects the human brain and&#xD;
      possible ways to reverse the changes associated with excess body weight. Subtle changes in&#xD;
      some brain regions occur in people who are overweight. Such changes may involve the&#xD;
      regulation of eating behavior, though it is not clear whether the changes were present before&#xD;
      weight gain or are a consequence. Magnetic resonance imaging (MRI) will be used to study&#xD;
      local structures of the brain.&#xD;
&#xD;
      Patients ages 18 to 45 who are undergoing gastric bypass surgery and who are not pregnant or&#xD;
      breastfeeding may be eligible for this study. A study group of lean participants will serve&#xD;
      as controls. Patients will visit the Phoenix Indian Medical Center for about 3 days at a time&#xD;
      for tests. They will have a medical examination, electrocardiogram, and tests of blood and&#xD;
      urine. Questionnaires they will complete involve patients' moods and possible influence on&#xD;
      eating behaviors, as well as food preferences. A taste test, smell test, and assessment of&#xD;
      decision-making processes will be conducted. An oral glucose tolerance test involves a needle&#xD;
      placed intravenously (IV) in the arm, for drawing blood after patients drink a sugar&#xD;
      solution. The test takes about 3-1/2 hours, with six blood samples taken (about 2 tablespoons&#xD;
      total). A meal test also includes use of an IV line. After patients consume a liquid meal,&#xD;
      blood will be collected to analyze levels of blood sugar and hormones. For the DEXA scan,&#xD;
      which measures body composition, patients will lie still while low-dose X-rays are used for 5&#xD;
      to 10 minutes. Urine will be collected for 1 whole day, to measure cortisol, a hormone. The&#xD;
      MRI scan uses a strong magnetic field to obtain images of body organs and tissues. Patients&#xD;
      having any metal in the body that may interfere with the scanning machine should not have&#xD;
      this test. For the MRI procedure, patients will lie on a table that slides into the enclosed&#xD;
      tunnel of the scanner and be asked to lie still. Patients will be able to communicate with&#xD;
      the MRI staff at all times during the scan, and they may ask to be removed from the machine&#xD;
      at any time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: We have identified subtle changes in some brain regions of obese subjects by&#xD;
      using a new computerized technique (voxel-based morphometry, VBM) which allows for studying&#xD;
      the local structure of the brain by taking very detailed pictures of the brain through&#xD;
      magnetic resonance imaging (MRI) and then processing these images with sophisticated&#xD;
      statistical software. Some of these regions may interfere with an obese person's ability to&#xD;
      predict future consequences of his or her eating behaviors. These changes may explain why&#xD;
      people have difficulty losing weight. However, it is not clear whether these changes in the&#xD;
      brain are present before or are a consequence of weight gain.&#xD;
&#xD;
      OBJECTIVES: The main aim of this study will be to evaluate the effects of a large and&#xD;
      intentional weight reduction on the brains of obese individuals for assessing the possible&#xD;
      reversal of the changes associated with excess body weight. Additional objectives will be a)&#xD;
      to determine the possible behavioral correlates of the changes in brain tissue composition&#xD;
      associated with a large and intentional weight reduction and b) to confirm the results of our&#xD;
      previous exploratory analysis showing that human obesity is associated with changes in brain&#xD;
      structure in areas related to the regulation of eating behavior.&#xD;
&#xD;
      DESIGN: This is a longitudinal protocol mainly focused on obese patients undergoing roux-en-Y&#xD;
      gastric bypass (RYGBP), which represents the most effective approach currently available to&#xD;
      achieving substantial weight loss, thus maximizing our chances of detecting significant&#xD;
      changes in brain tissue composition. Therefore, we propose to study brain morphology and the&#xD;
      metabolic and behavioral characteristics of 40 obese patients undergoing RYGBP prior to and&#xD;
      3, 6, 12, 24, and 48 months after the surgery. Forty lean subjects (at 0, 12, 24, and 48&#xD;
      months) will also be studied for comparison.&#xD;
&#xD;
      OUTCOME MEASURES: The volumes of the different components of the brain by VBM of MRI&#xD;
      pictures; metabolic parameters relevant to the relationship between obesity and the brain by&#xD;
      measuring fasting concentrations and postprandial responses of some metabolites; the ability&#xD;
      to regulate reward and behavior by specific tasks and questionnaires; the ability to detect&#xD;
      and discriminate smells by olfaction tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 24, 2006</start_date>
  <completion_date>October 3, 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>80</enrollment>
  <condition>Weight Loss</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
        Ethnicity: Caucasian, due to the cross-sectional analysis, upon which the present&#xD;
        longitudinal study is based, being made up of Caucasian subjects and the lack of normative&#xD;
        data in other racial and ethnic groups&#xD;
&#xD;
        Age 18-45 years, to minimize the confounding role of the well-known effects of aging on&#xD;
        brain tissue composition. There is, in fact, compelling evidence from post mortem and in&#xD;
        vivo studies that the brain shrinks with age. Neuropathological and CT and MRI morphometric&#xD;
        studies indicated that aging predominantly and substantially affects the GM. In addition,&#xD;
        deep WM lesions are seen on MRIs in approximately one-third of asymptomatic elderly&#xD;
        subjects. Blood pressure also rises with increasing age and can affect brain morphology.&#xD;
        Several studies provided evidence of specific patterns in the structural brain correlates&#xD;
        of aging, not only globally, between GM and WM compartments, but also locally, within&#xD;
        regions of the brain. Therefore, to limit the confounding effect of aging on brain tissue&#xD;
        composition, which could theoretically overlap with and confound those of weight loss, the&#xD;
        age limit for entering the study will be 45 years.&#xD;
&#xD;
        BMI greater than or equal to 35 kg/m(2) for group 1 and less than 25 kg/m(2) for group 2.&#xD;
&#xD;
        Weight less than or equal to 150 kg (maximum weight allowed on the MRI scanning tables by&#xD;
        the manufacturers).&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        History or clinical manifestation of:&#xD;
&#xD;
          -  Current smoking&#xD;
&#xD;
          -  Type 2 diabetes (according to the World Health Organization diagnostic criteria (63))&#xD;
&#xD;
          -  Endocrine disorders, such as Cushing's disease, pituitary disorders, and hypo- and&#xD;
             hyperthyroidism&#xD;
&#xD;
          -  Pulmonary disorders, including chronic obstructive pulmonary disease that would limit&#xD;
             ability to follow the protocol (investigator judgment) and obstructive sleep apnea&#xD;
             syndrome; only subjects with mild or exercise-induced asthma on no medications or on&#xD;
             beta-adrenergic agonists only (such as albuterol) will be allowed to enter the study&#xD;
&#xD;
          -  Cardiovascular diseases, including coronary heart disease, heart failure, arrhythmias,&#xD;
             and peripheral artery disease&#xD;
&#xD;
          -  Hypertension, as diagnosed and treated by an outside physician or by sitting blood&#xD;
             pressure measurement, using an appropriate cuff, higher than 140/90 mmHg on two or&#xD;
             more occasions&#xD;
&#xD;
          -  Gastrointestinal disease, including inflammatory bowel diseases (e.g. Crohn's disease&#xD;
             and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer&#xD;
             (active); only subjects with gastro-esophageal reflux will be allowed to enter the&#xD;
             study&#xD;
&#xD;
          -  Liver disease, including cirrhosis, active hepatitis B or C, and AST or ALT greater&#xD;
             than or equal to 3x normal&#xD;
&#xD;
          -  Renal disease, as defined by serum creatinine concentrations greater than or equal to&#xD;
             1.5 mg/dl and/or proteinuria greater than 300 mg/day (200 microgram/min)&#xD;
&#xD;
          -  Central nervous system disease, including previous history of cerebrovascular&#xD;
             accidents, dementia, and neurodegenerative disorders&#xD;
&#xD;
          -  Cancer requiring treatment in the past five years, except for non-melanoma skin&#xD;
             cancers or cancers that have clearly been cured or in the opinion of the investigator&#xD;
             carry an excellent prognosis (e.g., Stage 1 cervical cancer)&#xD;
&#xD;
          -  Conditions not specifically mentioned above may serve as criteria for exclusion at the&#xD;
             discretion of the investigators&#xD;
&#xD;
        Personal and/or family history of major psychiatric disorders based upon the DSM-IV (64),&#xD;
        including depression, schizophrenia, and psychosis, which may affect brain tissue&#xD;
        composition independent of obesity.&#xD;
&#xD;
        Medications acting on the central nervous system and steroidal drugs within 2 months of the&#xD;
        baseline study. Non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors, and&#xD;
        anti-acids will be allowed but discontinued 3 or more days before the admission.&#xD;
&#xD;
        Alcohol and/or drug abuse (more than 3 drinks per day and use of drugs, such as&#xD;
        amphetamines, cocaine, heroin, or marijuana).&#xD;
&#xD;
        Contra-indications for MRI, including pacemakers and/or ferromagnetic implants and&#xD;
        claustrophobia.&#xD;
&#xD;
        Pregnancy or lactation.&#xD;
&#xD;
        All subjects will be fully informed of the aim, nature, and risks of the study prior to&#xD;
        giving written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NIDDK, Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Regional Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002 Oct 9;288(14):1723-7.</citation>
    <PMID>12365955</PMID>
  </reference>
  <reference>
    <citation>Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003 Jul 14;163(13):1524-8.</citation>
    <PMID>12860573</PMID>
  </reference>
  <reference>
    <citation>Gustafson D, Lissner L, Bengtsson C, Bj√∂rkelund C, Skoog I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004 Nov 23;63(10):1876-81.</citation>
    <PMID>15557505</PMID>
  </reference>
  <verification_date>October 3, 2008</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Obesity</keyword>
  <keyword>Gray Matter</keyword>
  <keyword>Eating Behavior</keyword>
  <keyword>Brain MRI</keyword>
  <keyword>Body Weight Regulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

